Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 2008

View Archived Issues

Antisoma to acquire Xanthus Pharma for GBP 26.8 million

Dynavax reports results from Tolamba chamber study

Inspire receives milestone payment of USD 1.25 million from Santen

RETRA active against mutant p53-bearing cancer cells

Zinc finger protein transcription factors show potential in treating pain

Ki-20227 reduces the severity of experimental autoimmune encephalomyelitis

Antidepressants reduce HIV infectivity of monocyte-derived macrophages

Paliperidone palmitate effective in phase III schizophrenia study

Blocking mast cell chymase decreases pulmonary response in ovine asthma model

Phenomix's PHX-1149 demonstrates positive phase II results

Prepandrix pre-pandemic influenza vaccine approved in Europe

Pharmaxis' Aridol receives marketing approval in Germany

KaloBios initiates phase I/II trial of KB-001 for Pseudomonas aeruginosa infections

Positive phase IIa results reported for AgaNase in nasal decolonization of S. aureus

Ark reports an update on EG-013 and EG-014 preclinical programs

Pharmasset selects PSI-7851 as lead development candidate for treatment of HCV

Mymetics acquires preventive malaria vaccine from Pevion Biotech

Ikaria completes dosing in phase Ia clinical study of IK-1001 for injection

FDA grants fast track designation to InterMune's development of pirfenidone for IPF

Pro-Pharmaceuticals enters collaboration with BioCancell to deliver siRNA intravenously

Tibotec Therapeutics launches new 600 mg tablet strength for Prezista in HIV

New antidiabetic agents disclosed in recent patents

Recent patents report new therapeutic agents for obesity and other metabolic disorders

Novel agents for anxiety, depression described in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...